Lung Cancer News

A new study identified U.S. counties with high rates of lung cancer where travel times to a dedicated screening center exceed 60 minutes.

The FDA granted accelerated approval to lurbinectedin for adults with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy.

Fam-trastuzumab deruxtecan-nxki showed promising clinical activity among patients with HER2-mutant non-small cell lung cancer, according to interim results of the DESTINY-Lung01 trial presented during the ASCO20 Virtual Scientific Program.

First-line nivolumab with ipilimumab and a limited chemotherapy course significantly improved OS among patients with metastatic non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

The generalizability of the National Lung Screening Trial to community health settings was confirmed in a recent analysis, researchers said.

Nivolumab plus ipilimumab continued to provide long-term OS benefits compared with chemotherapy as initial treatment for advanced non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

The addition of durvalumab to chemotherapy appeared to confer a significant OS benefit as initial treatment for unresectable malignant pleural mesothelioma, according to study results presented during the ASCO20 Virtual Scientific Program.

The addition of pembrolizumab to chemotherapy provided long-term benefit to a subset of patients with advanced non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

Aggressive upfront stereotactic radiotherapy along with tyrosine kinase inhibitors increased PFS and OS for certain patients with non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

The FDA approved ramucirumab in combination with erlotinib for first-line treatment of patients with metastatic non-small cell lung cancer who have EGFR exon 19 deletions or exon 21 L858R mutations.